Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent advances in small-molecular therapeutics for COVID-19
Lei Zhong, Zhipeng Zhao, Xuerun Peng, et al.
Precision Clinical Medicine (2022) Vol. 5, Iss. 4
Open Access | Times Cited: 21

Showing 21 citing articles:

Molecules for COVID-19 treatment
Zhigang Zeng, Changzhou Liao, Lei Yu
Chinese Chemical Letters (2023) Vol. 35, Iss. 7, pp. 109349-109349
Closed Access | Times Cited: 14
Efficacy analysis and research progress of complementary and alternative medicines in the adjuvant treatment of COVID-19
Jaung‐Geng Lin, Guan‐Jhong Huang, Yi‐Chang Su
Journal of Biomedical Science (2023) Vol. 30, Iss. 1
Open Access | Times Cited: 10
Discovery of a Druggable, Cryptic Pocket in SARS-CoV-2 nsp16 Using Allosteric Inhibitors
Nicole L. Inniss, Ján Kozic, Fengling Li, et al.
ACS Infectious Diseases (2023) Vol. 9, Iss. 10, pp. 1918-1931
Open Access | Times Cited: 10
Macrocyclic Azapeptide Nitriles: Structure-Based Discovery of Potent SARS-CoV-2 Main Protease Inhibitors as Antiviral Drugs
Julian Breidenbach, Rabea Voget, Yaoyao Si, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 11, pp. 8757-8790
Closed Access | Times Cited: 3
SARS-CoV-2 Resistance to Small Molecule Inhibitors
Uxua Modrego Lopez, Md Mehedi Hasan, Brandon Havranek, et al.
Current Clinical Microbiology Reports (2024) Vol. 11, Iss. 3, pp. 127-139
Open Access | Times Cited: 3
Mercapto-pyrimidines are reversible covalent inhibitors of the papain-like protease (PLpro) and inhibit SARS-CoV-2 (SCoV-2) replication
Teena Bajaj, Eddie Wehri, Rahul K. Suryawanshi, et al.
RSC Advances (2023) Vol. 13, Iss. 26, pp. 17667-17677
Open Access | Times Cited: 5
Analogs of the Catechol Derivative Dynasore Inhibit HIV-1 Ribonuclease H, SARS-CoV-2 nsp14 Exoribonuclease, and Virus Replication
Abhishek Asthana, Angela Corona, Woo-Jin Shin, et al.
Viruses (2023) Vol. 15, Iss. 7, pp. 1539-1539
Open Access | Times Cited: 5
A Cell Based Assay Using Virus-like Particles to Screen AM Type Mimics for SARS-CoV-2 Neutralisation
Neeraj Gaur, Shreegauri Urankar, Durba Sengupta, et al.
Biochemical and Biophysical Research Communications (2024) Vol. 718, pp. 150082-150082
Closed Access | Times Cited: 1
Up, up, down, down: the structural biology of the SARS-CoV-2 spike protein and how it cheats the immune system
Sabrina Stäb, Nicholas M. Pearce, Dale E. Tronrud, et al.
Crystallography Reviews (2024), pp. 1-44
Open Access | Times Cited: 1
Real-world effectiveness of azvudine for patients infected with the SARS-CoV-2 omicron subvariant BA.5 in an intensive care unit
Xiuping QI, Yun Yang, Baoqiang Gong, et al.
Journal of Thoracic Disease (2023) Vol. 15, Iss. 9, pp. 4925-4937
Open Access | Times Cited: 3
Experimental evidence to the untapped potential of Ayurvedic herb, Ashwagandha: Bench-to-Bedside
Renu Wadhwa, Sunil C. Kaul
International Journal of Ayurveda Research (2023) Vol. 4, Iss. 1, pp. 15-27
Open Access | Times Cited: 3
Identification of 2,4-Diaminoquinazoline Derivative as a Potential Small-Molecule Inhibitor against Chikungunya and Ross River Viruses
Amrita Saha, Badri Narayan Acharya, Manmohan Parida, et al.
Viruses (2023) Vol. 15, Iss. 11, pp. 2194-2194
Open Access | Times Cited: 2
In Vitro Screening of an In-House Library of Structurally Distinct Chemotypes Towards the Identification of Novel SARS-CoV-2 Inhibitors
Michele Tonelli, Anna Sparatore, Ivan Bassanini, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 12, pp. 1668-1668
Open Access
Design, synthesis, and biological evaluation of novel 2'-deoxy-2'-spirooxetane-7-deazapurine nucleoside analogs as anti-SARS-CoV-2 agents.
Minli Gao, Zhaoyong Zhang, Guoqiang Yao, et al.
Antiviral Research (2024) Vol. 234, pp. 106060-106060
Closed Access
The Role of Structural Biology Task Force: Validation of the Binding Mode of Repurposed Drugs Against SARS-CoV-2 Protein Targets
Stefano Morasso, Elisa Costanzi, Nicola Demitri, et al.
SpringerBriefs in applied sciences and technology (2023), pp. 51-59
Closed Access | Times Cited: 1
Pairwise synthetic cytotoxicity between Paxlovid and 100 frequently prescribed FDA-approved small molecule drugs on liver cells
Zara Ahmad Khan, Yuli Hu, Behafarid Ghalandari, et al.
Toxicology and Applied Pharmacology (2023) Vol. 477, pp. 116695-116695
Closed Access | Times Cited: 1
Synthesis of 6,6-Dimethyl-3-azabicyclo [3.1.0]hexane via Ru (II)-Catalyzed Intramolecular Cyclopropanation
Yu Li, Yujie Ma, Shihao Cheng, et al.
Research Square (Research Square) (2023)
Open Access
Synthesis of 6,6-Dimethyl-3-azabicyclo [3.1.0]hexane via Ru (II)-catalyzed intramolecular cyclopropanation
Yu Li, Yujie Ma, Shihao Cheng, et al.
Medicinal Chemistry Research (2023) Vol. 32, Iss. 12, pp. 2501-2504
Open Access
In silico Analysis of Natural Products from Brazilian Biodiversity in COVID-19 Treatment: NuBBE Database against SARS-CoV-2 Papain-Like Protease
Caio Cheohen, Maria Eduarda Alves Esteves, Vinnícius Machado Schelk Gomes, et al.
Journal of the Brazilian Chemical Society (2023)
Open Access
Engineered Therapeutic Antibody Against SARS-CoV-2
Monrat Chulanetra
Current Clinical Microbiology Reports (2023) Vol. 10, Iss. 4, pp. 222-235
Closed Access
The implication and advantages of small-molecule drug
Tianyu Lu, Jiayi Yang
Theoretical and Natural Science (2023) Vol. 24, Iss. 1, pp. 76-80
Closed Access
Page 1

Scroll to top